samedan logo
 
 
spacer
home > ict > autumn 2008 > keeping trials on track
PUBLICATIONS
International Clinical Trials

Keeping Trials on Track

In today’s highly competitive biopharmaceutical marketplace, companies conducting clinical trials cannot afford delays in achieving critical study milestones – delays that can add millions of dollars to the cost of a trial. The intense pressure to bring innovative compounds to market as quickly and efficiently as possible makes it more important than ever for trial sponsors to keep clinical trials on track by closely monitoring site performance and data quality issues that could jeopardise study deadlines.

At the same time, biopharmaceutical trials are growing in complexity and scope. A typical Phase III trial might encompass thousands of patients at dozens of sites in multiple countries around the world. In addition, sponsors must supervise their trials diligently in order to meet growing demands from regulatory agencies to improve patient and drug safety. All of these challenges make it essential for sponsors to maintain the highest levels of scientific and ethical performance at trial sites.

Much of the day-to-day responsibility for meeting those challenges falls squarely on the shoulders of site monitors. They play a vital role in keeping the full range of site-based trial activities on schedule. Equally important, monitors ensure that...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
John Humphreys is a Principal Clinical Consultant in the
Product Management Group of Perceptive Informatics, a
leading eClinical technology provider. John is responsible
for product strategy and incorporation of client needs into
ongoing development of Perceptive’s clinical trial management
systems (CTMS). He has over 14 years of experience in the
biopharmaceutical industry, having held senior level positions
in software development. His background includes training as
a biochemist.
spacer
John Humphreys
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

BEERSE, BELGIUM, May 18, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.[i] Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.[ii],[iii] Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), duration of response, as well as the safety profile of amivantamab,1 which were the basis of the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation granted earlier this year.[iv]
More info >>

White Papers

Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies

PCI Pharma Services

Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex therapies not only increase risk in drug development but also drive costs even higher. A recent analysis of the investment needed to develop a new prescription medicine shows the total cost can be as high as $2.6 billion (1). That number becomes even more staggering when you consider the fact that only about 12 percent of drug candidates that make it to Phase I testing are eventually approved by the FDA (2). The investment companies lose as a result may be too devastating to their bottom line to ever recover.
More info >>

 
Industry Events

Outsourcing in Clinical Trials Europe

26-27 October 2020, Paris, France

Arena International are delighted to announce the return of Outsourcing in Clinical Trials Europe. Part of our global series of events, this flagship show will attract the leading clinical professionals from across Europe. The 10th Annual event will be hosted in Paris.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement